In today’s episode Craig talks us through a Dutch study on Neoadjuvant Chemoradiotherapy in pancreatic cancer. Hans also goes Dutch with a DRUP paper on rare cancers.
In quick bites we look at metastatic colorectal cancer, a vaccine for metastatic melanoma and lung cancer screening among Asian women. We’ve also analysis of the AACR report on COVID-19 and cancer research and a blow your own trumpet paper.
We hope you enjoy listening!
This Week’s Papers:
- Versteijne, E, et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. DOI: 10.1200/JCO.21.02233 Journal of Clinical Oncology. Published online January 27, 2022. Access online here.
- Hoes LR, et al. Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. Clin Cancer Res. 2022 Jan 19. doi: 10.1158/1078-0432.CCR-21-3752. Epub ahead of print. PMID: 35046062. Access online here.
- Gershenson DM, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022 Feb 5;399(10324):541-553. doi: 10.1016/S0140-6736(21)02175-9. PMID: 35123694; PMCID: PMC8819271. Access online here.
This Week’s Quick Bites:
- Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study. Access online here.
- Morris, V K., et al. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. Journal of Clinical Oncology 2022 40:4_suppl, 12-12. Access online here.
- Gallois C, et al. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. Dig Liver Dis. 2021 Oct;53(10):1254-1259. doi: 10.1016/j.dld.2021.06.009. Epub 2021 Jun 30. PMID: 34215534. Access online here.
- Kjeldsen JW, et al. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9. PMID: 34887574. Access online here.
- American Association for Cancer Research. AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care. Published February 9, 2022. Access online here. Or click here to download pdf report.
- Gao W, et al. Association of Computed Tomographic Screening Promotion With Lung Cancer Overdiagnosis Among Asian Women. JAMA Intern Med. 2022 Jan 18:e217769. doi: 10.1001/jamainternmed.2021.7769. Epub ahead of print. PMID: 35040922; PMCID: PMC8767491. Access online here.
Blow Your Own Trumpet Paper of The Week:
Wyart, E. Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia. EMBO Reports (2022)23:e53746. 24 February 2022. Access online here.
Other Episodes Mentioned:
The OJC 62: Sexual Desire in Female Cancer Survivors
This Week’s Team:
Associate Professor Craig Underhill
Craig Underhill
Associate Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program. You can find Craig on Twitter here: @CraigUnderhill
Professor Hans Prenen
Hans Prenen
Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings. His interests are clinical trials and translational research with a focus on digestive oncology. You can find Hans on Twitter here: @HPrenen
Rachael Babin
Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.
With thanks to Craig Underhill, Hans Prenen and Graham Knowles.
Connect with us on Twitter @OncologyNewsAus
